A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma - INCB 99280-212

Incyte Corp.0 个研究点目标入组 241 人开始时间: 2023年5月23日最近更新: 2024年7月22日

试验速览

阶段: 1 期
状态: 招募中
发起方: Incyte Corp.
入组人数: 241

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 65+（—）
性别: All

入选标准

•Ability to comprehend and willingness to sign a written ICF for the study., Age 18 years or older inclusive at the time of signing the ICF., Histopathological diagnosis of cSCC. Note: Tumors arising on the cutaneous hair-bearing portion of the lip with extension to the dry red lip (vermilion) are eligible if the origin of the primary tumor is known and clearly documented as the cutaneous hair-bearing portion of the lip. Participants with mixed histology are eligible if the predominant histology is cSCC., Previously untreated or recurrent locally advanced (without nodal metastases) or metastatic (distant or regional metastasis) cSCC not amenable to curative surgery and/or radiotherapy following consultation with a surgeon and/or radiation oncologist, respectively., Measurable disease based on either radiographic imaging per RECIST 1.1 with at least 1 baseline lesion = 10 mm in maximal diameter for metastatic disease or digital medical photography per WHO criteria with at least 1 baseline lesion in which both the longest diameter and the perpendicular diameter are = 10 mm for externally visible disease., ECOG performance status of 0 or 1 (see Section 8.3.4 of the protocol), Baseline archival tumor specimen available or willingness to undergo a pretreatment tumor biopsy to obtain a specimen for retrospective biomarker analysis. Must be a tumor block or 15 unstained slides (6 slides minimum) from biopsy or resection of primary tumor or metastasis that are = 1 year old (= 6 months for slides). It is preferred that the archival sample is from tissue obtained after completion of last treatment. Fine-needle aspirate and bone metastases samples are not acceptable, Life expectancy of > 3 months, in the opinion of the investigator., Willingness to avoid pregnancy or fathering children based on the criteria below. a. Men must agree to take appropriate precautions to avoid fathering children (with at least 99% certainty) from screening through 100 days after the last dose of study drug (or longer as appropriate based on country-specific requirements) and must refrain from donating sperm during this period. Permitted methods that are at least 99% effective in preventing pregnancy (see Appendix A) should be communicated to the participants and their understanding confirmed. b. WOCBP must meet the following criteria: - Have a negative serum pregnancy test at screening and agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through 190 days after the last dose of study treatment. Permitted methods that are at least 99% effective in preventing pregnancy (see Appendix A) should be communicated to the participants and their understanding confirmed. - Refrain from donating oocytes from 30 days before the first dose of study drug until 90 days after the last dose.

排除标准

•cSCC arising in the following locations: •Primary tumors of the vermilion only •Primary site of cancer on the penis, scrotum, and perianal region, History or evidence of interstitial lung disease, including noninfectious pneumonitis., Presence of gastrointestinal conditions that may affect drug absorption, as well as those that interfere with gastrointestinal transit, including gastric bypass surgery, gastric sleeve, or gastric band, Any autoimmune disease requiring systemic treatment in the past 5 years, including corticosteroids of a daily dose exceeding 10 mg of prednisone or equivalent., Diagnosis of primary immunodeficiency or receiving chronic systemic steroid therapy at a daily dose exceeding 10 mg of prednisone or equivalent., HIV infection and any one or more of the following: CD4+ T-cell count < 200 cells/µL, detectable viral load, or antiretroviral therapy regimen containing moderate or potent CYP3A4/CYP3A5 inhibitors or inducers. Note: Participants modifying their HIV regimen to include only drugs without CYP3A4/5 inhibitors or inducers must be on a stable regimen for > 28 days., Active infection requiring systemic therapy, with the exception of HIV and hepatitis as noted., History of organ transplantation, including allogeneic stem cell transplantation, Known hypersensitivity or severe reaction to any component of study drug or formulation components., Postoperative complications preventing the participant from adhering to protocol assessments and procedures., Receipt of systemic antibiotics within 28 days of first dose of study treatment., Known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of disease recurrence for 3 years since initiation of that therapy., Probiotic usage within 28 days of first dose of study treatment and while on study is prohibited., Received a live vaccine within 28 days of the planned start of study drug., Treatment with moderate and potent CYP3A4/CYP3A5 inhibitors or inducers (see Appendix E). Note: A washout period = 10 days before the first dose of INCB099280 is required for prior treatment with CYP3A4/CYP3A5 inhibitors/inducers., Unable to be weaned off of a prohibited medication as described in Section 6.6.3 before the initiation of study treatment, Laboratory values at screening as defined in Table 5., Clinically significant ECG abnormality, including QTcF interval > 480 milliseconds. Note: If a single ECG tracing at screening is > 480 milliseconds, the average of a triplicate ECG may be used., Active HBV or HCV infection defined as follows (testing must be performed to determine eligibility): a. Detectable HBV DNA and HBsAg positive. b. A positive HCV antibody and quantitative HCV RNA result greater than the lower limit of detection for the assay., Pregnant, expecting to conceive, or breastfeeding starting with the screening visit through 190 days after the last dose of study treatment or expecting to father children starting with the screening visit through 100 days after the last dose of study treatment., Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits, pose a significant risk to the participant, or interfere with interpretation of study data, The following participants are excluded in France: vulnerable populations according to article L.1121-6 of the French Public Health Co

研究者

发起方

Incyte Corp.

相似试验

招募中

1 期

CTIS2022-502716-37-00Incyte Corp.328

进行中（未招募）

2 期

A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaiveAdvanced Solid Tumor

NCT05879822Incyte Corporation73

进行中（未招募）

2 期

A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell CarcinomaCutaneous Squamous Cell Carcinoma

NCT05888844Incyte Corporation63

招募中

1 期

A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C MutatioAdvanced Solid Tumors Harboring a KRASG12C MutationMedDRA version: 21.1Level: PTClassification code: 10029515Term: Non-small cell lung cancer recurrent Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10059515Term: Non-small cell lung cancer metastatic Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029522Term: Non-small cell lung cancer stage IV Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 20.0Level: LLTClassification code: 10010036Term: Colorectal carcinoma Class: 10029104

CTIS2023-503223-26-00Incyte Corp.125

进行中（未招募）

1 期

CTIS2023-503243-34-00Incyte Corp.124